TY - JOUR
T1 - “Sarcomatoid” carcinomas of the lung
T2 - a clinicopathological study of 86 cases with a new perspective on tumor classification
AU - Weissferdt, Annikka
AU - Kalhor, Neda
AU - Correa, Arlene M.
AU - Moran, Cesar A.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Pulmonary sarcomatoid carcinoma includes a heterogenous group of tumors difficult to diagnose and treat. We report the clinicopathological features of 86 such tumors, including 74 pleomorphic and 12 spindle cell carcinomas, and propose a novel approach to the classification of these neoplasms in an attempt to better guide patient management. The patients were 47 men and 39 women aged 36 to 87 years (mean, 63 years) who primarily presented with shortness of breath, cough, and chest pain. Eighty-six percent of patients had a smoking history. Histologically, the pleomorphic carcinomas consisted of spindle and/or giant cells with varying proportions of conventional non–small cell carcinoma in the form of adenocarcinoma (n = 29), squamous cell carcinoma (n = 10), or large cell carcinoma (n = 18); 17 cases contained a mix of spindle and giant cells only. The 12 spindle cell carcinomas consisted of spindle cells only. Based on the combined histopathologic and immunohistochemical features of these tumors, we were able to reanalyze the spectrum of these lesions and reclassify them accordingly. Statistical analysis revealed an overall survival at 3, 5, and 10 years of 42.9%, 34.6%, and 23.5%, respectively, and a median survival of 15 months. Log-rank test showed that in multivariate analysis, only pathological T stage was a factor associated with prognosis. The current classification of pulmonary sarcomatoid carcinomas precludes optimal triaging of these tumors with the risk of denying patients access to novel treatment. Our proposal for a reclassification of these tumors would more accurately guide patient management and facilitate targeted therapies.
AB - Pulmonary sarcomatoid carcinoma includes a heterogenous group of tumors difficult to diagnose and treat. We report the clinicopathological features of 86 such tumors, including 74 pleomorphic and 12 spindle cell carcinomas, and propose a novel approach to the classification of these neoplasms in an attempt to better guide patient management. The patients were 47 men and 39 women aged 36 to 87 years (mean, 63 years) who primarily presented with shortness of breath, cough, and chest pain. Eighty-six percent of patients had a smoking history. Histologically, the pleomorphic carcinomas consisted of spindle and/or giant cells with varying proportions of conventional non–small cell carcinoma in the form of adenocarcinoma (n = 29), squamous cell carcinoma (n = 10), or large cell carcinoma (n = 18); 17 cases contained a mix of spindle and giant cells only. The 12 spindle cell carcinomas consisted of spindle cells only. Based on the combined histopathologic and immunohistochemical features of these tumors, we were able to reanalyze the spectrum of these lesions and reclassify them accordingly. Statistical analysis revealed an overall survival at 3, 5, and 10 years of 42.9%, 34.6%, and 23.5%, respectively, and a median survival of 15 months. Log-rank test showed that in multivariate analysis, only pathological T stage was a factor associated with prognosis. The current classification of pulmonary sarcomatoid carcinomas precludes optimal triaging of these tumors with the risk of denying patients access to novel treatment. Our proposal for a reclassification of these tumors would more accurately guide patient management and facilitate targeted therapies.
KW - Classification
KW - Immunohistochemistry
KW - Lung
KW - Non–small cell carcinoma
KW - Pleomorphic carcinoma
KW - Sarcomatoid carcinoma
KW - Spindle cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85016306018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016306018&partnerID=8YFLogxK
U2 - 10.1016/j.humpath.2016.12.010
DO - 10.1016/j.humpath.2016.12.010
M3 - Article
C2 - 27993578
AN - SCOPUS:85016306018
SN - 0046-8177
VL - 63
SP - 14
EP - 26
JO - Human Pathology
JF - Human Pathology
ER -